BridgeBio Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

BridgeBio Pharma wird ein Gewinn- und Umsatzwachstum von 48.1% bzw. 39.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 46.9% pro Jahr wachsen soll.

Wichtige Informationen

38.6%

Wachstumsrate der Gewinne

37.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	41.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sep 24

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 31

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Aug 17

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jul 02

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

May 09

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Feb 28

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Jan 09

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

Oct 11

BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU

Sep 20

BridgeBio Pharma: Down But Not Out

Aug 31

BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders

Aug 18

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BBIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	519	-429	-431	-402	11
12/31/2025	220	-597	-569	-489	15
12/31/2024	356	-427	-330	-354	15
6/30/2024	219	-454	-420	-415	N/A
3/31/2024	219	-538	-606	-603	N/A
12/31/2023	9	-643	-529	-528	N/A
9/30/2023	9	-613	-498	-496	N/A
6/30/2023	6	-573	-488	-486	N/A
3/31/2023	78	-425	-409	-403	N/A
12/31/2022	78	-481	-426	-419	N/A
9/30/2022	89	-491	-468	-460	N/A
6/30/2022	91	-509	-495	-447	N/A
3/31/2022	71	-596	-555	-508	N/A
12/31/2021	70	-563	-546	-498	N/A
9/30/2021	57	-535	-508	-460	N/A
6/30/2021	63	-495	-477	-470	N/A
3/31/2021	9	-520	-472	-467	N/A
12/31/2020	8	-449	-407	-400	N/A
9/30/2020	22	-402	-387	-380	N/A
6/30/2020	41	-346	-305	-298	N/A
3/31/2020	41	-291	-286	-278	N/A
12/31/2019	41	-261	-256	-254	N/A
9/30/2019	27	-226	-228	-224	N/A
6/30/2019	N/A	-197	-216	-212	N/A
3/31/2019	N/A	-155	-183	-178	N/A
12/31/2018	N/A	-131	-155	-137	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BBIO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BBIODie Einnahmen des Unternehmens (39.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: BBIODie Einnahmen des Unternehmens (39.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BBIO in 3 Jahren voraussichtlich hoch sein wird

BridgeBio Pharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

Consensus revenue estimates increase by 83%

Consensus revenue estimates increase by 44%

Recent updates

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

BridgeBio Pharma, Inc. Presents Additional Data from an Analysis of its Phase 3 ATTRibute-CM and Open-Label Extension Study of Acoramidis in ATTR-CM at the European Society of Cardiology 2024

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. and QED Therapeutics Announce the Launch of the Initial Phase of MyAchonJourney

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

New major risk - Financial position

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BridgeBio Pharma, Inc. Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Consensus revenue estimates increase by 11%

CFO & Secretary exercised options and sold US$433k worth of stock

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

Consensus revenue estimates increase by 83%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

Consensus revenue estimates increase by 44%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 81%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder exercised options and sold US$1.8m worth of stock

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

Consensus revenue estimates fall by 25%

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 22% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Consensus EPS estimates fall by 11%, revenue upgraded

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 13%

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

Price target increased by 20% to US$33.90

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

CFO & Secretary exercised options and sold US$632k worth of stock

Price target increased by 8.3% to US$28.40

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Co-Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 105%

Price target increased by 8.6% to US$23.90

Consensus revenue estimates decrease by 53%, EPS upgraded

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Key Executive notifies of intention to sell stock

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)